关注
Niels Vermeer
Niels Vermeer
Pharmacoepidemiology & Clinical pharmacology, Utrecht University
在 uu.nl 的电子邮件经过验证
标题
引用次数
引用次数
年份
Perinatal morbidity and mortality in early‐onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE)
C Lees, N Marlow, B Arabin, CM Bilardo, C Brezinka, JB Derks, J Duvekot, ...
Ultrasound in obstetrics & gynecology 42 (4), 400-408, 2013
800*2013
Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases
NS Vermeer, SMJM Straus, AK Mantel-Teeuwisse, F Domergue, ...
Drug safety 36, 617-625, 2013
822013
Traceability of biologicals: present challenges in pharmacovigilance
NS Vermeer, I Spierings, AK Mantel-Teeuwisse, SMJM Straus, TJ Giezen, ...
Expert Opinion on Drug Safety 14 (1), 63-72, 2015
662015
Utilization of evidence‐based therapy for the secondary prevention of acute coronary syndromes in Australian practice
NS Vermeer, BV Bajorek
Journal of clinical pharmacy and therapeutics 33 (6), 591-601, 2008
432008
Traceability of biologics in The Netherlands: an analysis of information-recording systems in clinical practice and spontaneous ADR reports
K Klein, JHG Scholl, NS Vermeer, AW Broekmans, EP Van Puijenbroek, ...
Drug Safety 39, 185-192, 2016
402016
Risk management plans as a tool for proactive pharmacovigilance: a cohort study of newly approved drugs in Europe
NS Vermeer, RG Duijnhoven, S Straus, AK Mantel‐Teeuwisse, PR Arlett, ...
Clinical Pharmacology & Therapeutics 96 (6), 723-731, 2014
362014
Identifiability of biologicals in adverse drug reaction reports received from European clinical practice
NS Vermeer, TJ Giezen, S Zastavnik, E Wolff‐Holz, A Hidalgo‐Simon
Clinical Pharmacology & Therapeutics 105 (4), 962-969, 2019
342019
Drug‐induced progressive multifocal leukoencephalopathy: lessons learned from contrasting natalizumab and rituximab
NS Vermeer, S Straus, AK Mantel‐Teeuwisse, A Hidalgo‐Simon, ...
Clinical Pharmacology & Therapeutics 98 (5), 542-550, 2015
262015
The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product‐specific risks for biologicals: a simulation study
NS Vermeer, HC Ebbers, SMJM Straus, HGM Leufkens, TCG Egberts, ...
pharmacoepidemiology and drug safety 25 (3), 297-306, 2016
132016
Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: an observational study
EA Basak, NS Vermeer, K de Joode, DP Hurkmans, DEM Velthuis, ...
European Journal of Cancer 174, 113-120, 2022
112022
Strategy in Regulatory Decision‐Making for Management of Progressive Multifocal Leukoencephalopathy
A Segec, B Keller‐Stanislawski, NS Vermeer, C Macchiarulo, SM Straus, ...
Clinical Pharmacology & Therapeutics 98 (5), 502-505, 2015
62015
Harmful Effects of Proton Pump Inhibitors: Discrepancies Between Observational Studies and Randomized Clinical Trials—Reply
M Maggio, A Corsonello
JAMA Internal Medicine 173 (16), 1559-1560, 2013
62013
Sparse Batch Number Reporting for Biologicals in FDA's Adverse Event Reporting System (AERS)
NS Vermeer, SM Straus, AK Teeuwisse, TC Egberts, HG Leufkens, ...
DRUG SAFETY 34 (10), 1002-1002, 2011
12011
1863P Incidence and predictors of severe adverse events during anti-PD-1 treatment
EA Basak, NS Vermeer, KD Joode, DP Hurkmans, DEM Velthuis, ...
Annals of Oncology 32, S1251-S1252, 2021
2021
2.2 Traceability of biologics in the
K Klein, JHG Scholl, NS Vermeer, AW Broekmans, EP van Puijenbroek, ...
edicines 39, 43, 2016
2016
Pharmacovigilance of biologicals: dynamics in post-approval safety learning
NS Vermeer
Utrecht University, 2015
2015
3.2 The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals
NS Vermeer, HC Ebbers, S Straus, HGM Leufkens, ACG Egberts, ...
Pharmacovigilance of biologicals, 75, 2015
2015
4.2 Cancer risks of medicines approved in the European Union: what is known at licensing and what is solved post-marketing?
RG Duijnhoven, NS Vermeer, S Straus, AW Hoes, AT de Boer, ...
Pharmacovigilance of biologicals, 133, 2015
2015
3.1 Traceability of biopharmaceuticals in spontaneous reporting systems: sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases
NS Vermeer, S Straus, AK Mantel-Teeuwisse, F Domergue, ACG Egberts, ...
Pharmacovigilance of biologicals 36, 57, 2015
2015
2.2 Analytical interference by monoclonal antibodies in frequently used immunoassays: an in vitro study
NS Vermeer, ML De Bruin, ACG Egberts, WW van Solinge, E Lentjes
Pharmacovigilance of biologicals, 43, 2015
2015
系统目前无法执行此操作,请稍后再试。
文章 1–20